Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effects of Atomoxetine Treatment in Humans
This study is ongoing, but not recruiting participants.
Sponsors and Collaborators: Yale University
Department of Veterans Affairs
Information provided by: Yale University
ClinicalTrials.gov Identifier: NCT00611936
  Purpose

A total of 18 healthy volunteers will participate in this four-week, within-groups, double-blind, placebo-controlled study. The study has two phases separated by a 4 to 15-day washout period. Subjects will be randomly assigned to receive either 40 mg atomoxetine or placebo. For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. After receiving medication or placebo for three days, subjects will have a 6-hour laboratory session, where responses to physical and psychological stress of a 20 mg/70 kg (20 mg maximum) dose of d-amphetamine will be measured. Several physiological, hormonal, and subjective outcome measures will be obtained during the experimental sessions. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II.


Condition Intervention Phase
Stress
Drug: Placebo
Drug: Atomoxetine
Phase I
Phase II

MedlinePlus related topics: Methamphetamine
Drug Information available for: Atomoxetine Atomoxetine hydrochloride Dextroamphetamine Dextroamphetamine sulfate Amphetamine Amphetamine sulfate Methamphetamine
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Crossover Assignment, Efficacy Study
Official Title: Effects of Atomoxetine Treatment in Humans

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Measuring subjective responses to physical and psychological models of stress and oral amphetamine in healthy volunteers. [ Time Frame: one year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 18
Study Start Date: June 2006
Estimated Study Completion Date: June 2008
Estimated Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
2: Placebo Comparator
Second arm is placebo
Drug: Placebo
Placebo
1: Experimental
One arm is atomoxetine 40 mg per day
Drug: Atomoxetine
20mg maximum of d-amphetamine

Detailed Description:

Objective: This pilot study will examine the effects of a norepinephrine reuptake blocker, atomoxetine, on physiological and subjective responses to physical and psychological models of stress and oral amphetamine in healthy volunteers. The physical stress model will be the cold pressor test (CPT) and the psychological stress will be the paced auditory serial addition task (PASAT).

Our overall hypothesis is that atomoxetine treatment, compared to placebo, will attenuate the physiological and subjective responses to stress and d-amphetamine.

2. Research Design: Double-blind, placebo-controlled, within-groups, outpatient study.

3. Methodology: A total of 18 healthy volunteers will participate in this four-week, within-groups, double-blind, placebo-controlled study. The study has two phases separated by a 4 to 15-day washout period. Subjects will be randomly assigned to receive either 40 mg atomoxetine or placebo. For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. After receiving medication or placebo for three days, subjects will have a 6-hour laboratory session, where responses to physical and psychological stress of a 20 mg/70 kg (20 mg maximum) dose of d-amphetamine will be measured. Several physiological, hormonal, and subjective outcome measures will be obtained during the experimental sessions. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female and males, age 18 to 45 years
  • Current history of good health and normal ECG
  • For women: not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods.

Exclusion Criteria:

  • History of heart disease, hypertension, renal or hepatic diseases, glaucoma, hyperthyroidism, or other medical conditions that the physician investigator deems as contraindicated for the patient to be in the study
  • Current use of psychotropic medication(antidepressants, antipsychotics, or anxiolytics) and/or diagnosis and treatment for Axis I disorders including major depression, bipolar affective disorder, schizophrenia and panic disorder within the past year.
  • Current dependence on alcohol or on drugs or treatment for drug or alcohol addiction(amphetamines have greater abuse liability among those with drug addictions) within the past 5 years.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00611936

Sponsors and Collaborators
Yale University
Investigators
Principal Investigator: Mehmet Sofuoglu, M.D., Ph.D. Yale University
  More Information

Responsible Party: Yale University ( Mehmet Sofuoglu M.D., Ph.D. )
Study ID Numbers: 0605001441
Study First Received: January 29, 2008
Last Updated: February 8, 2008
ClinicalTrials.gov Identifier: NCT00611936  
Health Authority: United States: Institutional Review Board

Keywords provided by Yale University:
Atomoxetine
Stress
d-amphetamine

Study placed in the following topic categories:
Methamphetamine
Dextroamphetamine
Atomoxetine
Stress
Amphetamine

Additional relevant MeSH terms:
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009